Details of the Drug

General Information of Drug (ID: DM8LNMY)

Drug Name
N-methyl-2-(pyridin-2-yl)ethanamine
Synonyms
betahistine; 5638-76-6; 2-(2-METHYLAMINOETHYL)PYRIDINE; Vasomotal; Serc base; 2-Pyridineethanamine, N-methyl-; beta-Histine; PT 9 base; Sinmenier (free base); methyl[2-(pyridin-2-yl)ethyl]amine; Betahistina; Betahistinum; 2-[2-(Methylamino)ethyl]pyridine; N-Methyl-2-pyridineethylamine; N-Methyl-2-pyridineethanamine; Betaistina [DCIT]; Serc; Betahistine [INN:BAN]; 2-(2-(Methylamino)ethyl)pyridine; N-methyl-2-pyridin-2-ylethanamine; Betahistinum [INN-Latin]; Betahistina [INN-Spanish]
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Affected Organisms
Humans and other mammals
ATC Code
N07CA01: N-methyl-2-(pyridin-2-yl)ethanamine
N07CA: Antivertigo preparations
N07C: ANTIVERTIGO PREPARATIONS
N07: OTHER NERVOUS SYSTEM DRUGS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 136.19
Logarithm of the Partition Coefficient (xlogp) 0.4
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1 h [2]
Elimination
Betahistine is mainly excreted in the urine with approximately 85-91% being detected in urine samples within 24 hours of administration [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 - 4 hours [2]
Metabolism
The drug is metabolized to the inactive metabolite 2-pyridylacetic acid []
Chemical Identifiers
Formula
C8H12N2
IUPAC Name
N-methyl-2-pyridin-2-ylethanamine
Canonical SMILES
CNCCC1=CC=CC=N1
InChI
InChI=1S/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3
InChIKey
UUQMNUMQCIQDMZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2366
ChEBI ID
CHEBI:35677
CAS Number
5638-76-6
UNII
X32KK4201D
DrugBank ID
DB06698
TTD ID
D0XW9U

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H3 receptor (H3R) TT9JNIC HRH3_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H3 receptor (H3R) DTT HRH3 3.62E-02 -0.09 -0.22
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity. J Med Chem. 2009 Jul 9;52(13):3855-68.
2 Pharmacokinetics and dose proportionality of betahistine in healthy individuals Scientia Pharmaceutica.
3 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.